Skip to main content

previous disabled Page of 2
and
  1. No Access

    Article

    Arming the regulators — new strategies to treat autoimmunity

    A great deal of interest exists in the use of regulatory T cells for therapeutic purposes in autoimmune diseases such as rheumatoid arthritis. Two new studies highlight possible approaches to achieve this aim,...

    Richard O. Williams, Wen-Yi Tseng in Nature Reviews Rheumatology (2018)

  2. Article

    Open Access

    Response to Treatment with TNFα Inhibitors in Rheumatoid Arthritis Is Associated with High Levels of GM-CSF and GM-CSF+ T Lymphocytes

    Biologic TNFα inhibitors are a mainstay treatment option for patients with rheumatoid arthritis (RA) refractory to other treatment options. However, many patients either do not respond or relapse after initial...

    Jonas Bystrom, Felix I. Clanchy, Taher E. Taher in Clinical Reviews in Allergy & Immunology (2017)

  3. Article

    Open Access

    Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis

    Anti-TNF agents have revolutionised rheumatoid arthritis (RA) treatment; however, a third of patients fail to achieve therapeutic responses. Unexpectedly, studies in murine and human arthritis have indicated t...

    Dobrina N. Hull, Helen Cooksley, Shilpa Chokshi in Arthritis Research & Therapy (2016)

  4. Article

    Open Access

    Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of T cell-mediated immune responses

    Proteins containing citrulline, a post-translational modification of arginine, are generated by peptidyl arginine deiminases (PAD). Citrullinated proteins have pro-inflammatory effects in both innate and adapt...

    Joanna Kawalkowska, Anne-Marie Quirke, Fatemeh Ghari, Simon Davis in Scientific Reports (2016)

  5. Article

    Open Access

    Applying refinement to the use of mice and rats in rheumatoid arthritis research

    Rheumatoid arthritis (RA) is a painful, chronic disorder and there is currently an unmet need for effective therapies that will benefit a wide range of patients. The research and development process for thera...

    Penny Hawkins, Rachel Armstrong, Tania Boden, Paul Garside in Inflammopharmacology (2015)

  6. No Access

    Chapter

    Role of the Kynurenine Pathway in Immune-Mediated Inflammation

    Indoleamine 2,3-dioxygenase (IDO) plays a key role in immune homeostasis via depletion of tryptophan and accumulation of kynurenines and is recognized as an important factor contributing to suppression of anti...

    Adam P. Cribbs, Richard O. Williams in Targeting the Broadly Pathogenic Kynurenine Pathway (2015)

  7. No Access

    Article

    Kynurenine metabolism in health and disease

    Kynurenine is a small molecule derived from tryptophan when this amino acid is metabolised via the kynurenine pathway. The biological activity of kynurenine and its metabolites (kynurenines) is well recognised...

    Lukasz R. Kolodziej, Ewa M. Paleolog, Richard O. Williams in Amino Acids (2011)

  8. Article

    Open Access

    Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis

    Type 4 phosphodiesterases (PDE4) play an important role in immune cells through the hydrolysis of the second messenger, cAMP. Inhibition of PDE4 has previously been shown to suppress immune and inflammatory re...

    Fiona E McCann, Andrew C Palfreeman, Melanie Andrews in Arthritis Research & Therapy (2010)

  9. Article

    Paradoxical effects of tumour necrosis factor-α in adjuvant-induced arthritis

    Anti-tumour necrosis factor (TNF)α therapy is highly effective in rheumatoid arthritis and it is surprising, therefore, that a recent study showed that intraperitoneal administration of recombinant TNFα reduce...

    Richard O Williams in Arthritis Research & Therapy (2008)

  10. No Access

    Article

    Protocol for the induction of arthritis in C57BL/6 mice

    Collagen-induced arthritis is a well-validated, but strain-dependent mouse model of rheumatoid arthritis, with H-2q and H-2r strains showing the greatest degree of susceptibility. This protocol describes the indu...

    Julia J Inglis, Egle Šimelyte, Fiona E McCann, Gabriel Criado in Nature Protocols (2008)

  11. Article

    Open Access

    Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen

    Many genetically modified mouse strains are now available on a C57BL/6 (H-2b) background, a strain that is relatively resistant to collagen-induced arthritis. To facilitate the molecular understanding of autoimmu...

    Julia J Inglis, Gabriel Criado, Mino Medghalchi in Arthritis Research & Therapy (2007)

  12. No Access

    Protocol

    Collagen-Induced Arthritis in Mice

    Collagen-induced arthritis in mice has been widely used to address questions of disease pathogenesis and to validate therapeutic targets for human rheumatoid arthritis. Arthritis is normally observed about 3 w...

    Richard O. Williams in Arthritis Research (2007)

  13. No Access

    Protocol

    Collagen-Induced Arthritis in Mice

    Collagen-induced arthritis is the most widely used animal model for the evaluation of novel therapeutic strategies for rheumatoid arthritis. The disease is induced by immunization of genetically susceptible st...

    Richard O. Williams in Target Discovery and Validation Reviews and Protocols (2007)

  14. No Access

    Protocol

    Collagen-Induced Arthritis as a Model for Rheumatoid Arthritis

    Collagen-induced arthritis (CIA) is an animal model of rheumatoid arthritis (RA) that is widely used to address questions of disease pathogenesis and to validate therapeutic targets. Arthritis is normally indu...

    Richard O. Williams in Tumor Necrosis Factor (2004)

  15. Article

    Interleukin-1 Receptor Antagonist Isoforms in Collagen-Induced Arthritis

    Cem Gabay, Richard O Williams, Debra M Butler in Arthritis Research & Therapy (1999)

  16. No Access

    Article

    Combination therapy in mice: what can we learn that may be useful for understanding rheumatoid arthritis?

    Richard O. Williams in Springer Seminars in Immunopathology (1998)

  17. No Access

    Article

    Are there two classes of VSG gene in Trypanosoma brucei?

    Antigenic variation in the African trypanosomes involves the sequential expression of genes coding for different variant surface glycoproteins (VSGs) (reviewed in refs 1–3). When expression of some VSG genes i...

    John R. Young, E. Nancy Miller, Richard O. Williams, Mervyn J. Turner in Nature (1983)

  18. No Access

    Article

    DNA rearrangements linked to expression of a predominant surface antigen gene of trypanosomes

    African trypanosomes show an extensive capacity for antigenic variation1–6. The serotype of each antigenic variant is determined by a variant-specific surface antigen (VSA) which forms a continuous coat over the ...

    Monique Laurent, Etienne Pays, Eddy Magnus, Nestor Van Meirvenne in Nature (1983)

  19. No Access

    Article

    Genomic environment of T. brucei VSG genes: presence of a minichromosome

    Restriction endonuclease maps of some trypanosome variant surface glycoprotein (VSG) genes have a site 3′ to the gene where many enzymes appear to cut. This site is sensitive to Bal31 exonuclease, indicating a na...

    Richard O. Williams, John R. Young, Phelix A. O. Majiwa in Nature (1982)

  20. No Access

    Article

    Two distinct forms of surface antigen gene rearrangement in Trypanosoma brucei

    African trypanosomes express different surface antigens sequentially in their mammalian hosts1. Expression of different variable surface glycoprotein (VSG) antigens is associated with rearrangements of genomic DN...

    Phelix A. O. Majiwa, John R. Young, Paul T. Englund, Stuart Z. Shapiro in Nature (1982)

previous disabled Page of 2